What does the FDA’s approval of leucovorin mean?
The FDA has approved leucovorin for cerebral folate deficiency, a rare genetic condition affecting about 1 in 1 million people. This decision has sparked significant interest, particularly among parents of children with autism, who have reported improvements in their children’s symptoms after using the drug.
Leucovorin, also known as folinic acid, is a high-dose B vitamin primarily used to counteract chemotherapy side effects. Since 2009, it has been utilized to treat folate deficiency, but its recent approval specifically targets cerebral folate deficiency, which limits the delivery of folate to the brain, affecting thinking, speech, and movement.
What led to this moment?
Fewer than 50 cases of cerebral folate deficiency have been identified worldwide, and the FDA’s approval was based on a systematic literature review that included case reports and mechanistic data. However, the agency has stated that there is insufficient evidence to support the use of leucovorin for autism treatment.
Following a White House briefing in September, prescriptions for leucovorin surged by 71%, making the drug difficult to find. This increase was fueled by previous suggestions from the FDA that leucovorin could be a potential treatment for autism, despite the lack of robust evidence.
What do experts say?
Experts have expressed concern over the rush to use leucovorin for autism. Dr. I. David Goldman remarked, “The damage is done, because parents with autistic kids are desperate.” Meanwhile, an FDA official stated, “We don’t have sufficient data to say that we could establish efficacy for autism more broadly.”
Additionally, the largest randomized double-blind, placebo-controlled trial testing leucovorin for autism was retracted due to errors, further complicating the narrative surrounding its use.
What comes next?
The FDA remains open to interest from companies studying leucovorin in the autism population, yet details remain unconfirmed regarding future studies on its efficacy for this condition. The long-term effects of leucovorin on children with autism are also not well-documented, leaving many questions unanswered.
As the conversation around leucovorin continues, it highlights the ongoing challenges faced by families seeking effective treatments for autism and the importance of rigorous scientific validation in medical therapies.
